Abstract
Structure-based design approach was successfully used to guide the evolution of a pyrazolo[3,4-d]pyrimidine scaffold yielding a new structural class of highly selective inhibitors of cyclin dependent kinases capable to interact with an identified part of the protein. Several compounds from this series displayed potent and selective activity against CDK2.